

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES


LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

The Possible Local Synthesis of Antibodies to Herpes Simplex Virus in Normal Cerebrospinal Fluid	<i>Anthony Science Russell</i>	219
A Theory of the Mechanism of Cerebral Vasospasm and Its Reversal, the role of Calcium and Cyclic AMP	<i>Eric W. Peterson, Richard Leblanc</i>	223
Neurofibrillary Tangles in the Dementia of "Normal Pressure" Hydrocephalus	<i>Melvyn J. Ball</i>	227
Some Neurophysiological Effects of Cerebellar Stimulation in Man	<i>Adrian R. M. Upton, Irving S. Cooper</i>	237
The Reactivity of Canine Cerebral Arteries to O₂ and CO₂ in Vitro	<i>P. Steinbok, M. J. Kendal, R. J. Clarke, S. J. Peerless</i>	255
Supplemental Abstracts — Addendum to the Programme of the XI Congress of Neurological Sciences		
I.C.P. Aneurysms and Subarachnoid Hemorrhage	<i>S. J. Peerless, N. F. Kassell</i>	263
Visual Evoked Potentials in Leber's Hereditary Optic Neuropathy	<i>L. J. Dorfman</i>	263
Announcements and Books Received		265
Quebec Cooperative Study on Friedreich's Ataxia		269
Quebec Cooperative Study of Friedreich's Ataxia: Design of the Investigation	<i>A. Barbeau</i>	271
Nicolaus Friedreich and Degenerative Atrophy of the Posterior Columns of the Spinal Cord	<i>F. Andermann</i>	275
Clinical Description and Roentgenologic Evaluation of Patients with Friedreich's Ataxia	<i>G. Geoffroy, A. Barbeau, G. Breton, B. Lemieux, M. Aube, C. Leger, and J. B. Bouchard</i>	279
Genetic and Family Studies in Friedreich's Ataxia	<i>E. Andermann, G. M. Remillard, C. Goyer, L. Blitzer and A. Barbeau</i>	287
Friedreich's Ataxia: Preliminary Results of Some Genealogical Research	<i>A. Barbeau, M. LeSeige, G. Breton, R. Coallier and J. P. Bouchard</i>	303

Continued on page iv

QUEBEC COOPERATIVE STUDY ON FRIEDREICH'S ATAXIA — PHASE ONE

For the management of Vertigo in Meniere's disease



TABLETS
SERC[®]
(Betahistine hydrochloride)

histaminic – not antihistaminic
often a more helpful approach

Clinical Features

Chemically Unique Vasoactive Compound

- Vascular responses similar to those of histamine^{1, 2}
- Tends to restore, not depress vestibular response^{3, 4}

May Increase Blood Flow To Inner Ear

- Increases cochlear blood flow in experimental animals^{5, 6}
- Increases basilar and labyrinthine artery flow in canine studies^{7, 8}

Demonstrated Efficacy and Patient Acceptance

- Reduces the number and severity of vertigo attacks^{9, 10}
- Suitable for long term management^{9, 10}
- Effective when other medications failed^{9, 10}
- Well tolerated^{2, 3, 4, 9, 10}

REFERENCES

1. Hunt, W. H., and Fosbinder, R. J.: A study of some beta-2, and 4, pyridylalkylamines. *J. Pharmacol. & Exper. Therap.* 75:299 (August) 1942.
2. Horton, B. T., and von Leden, H.: Clinical use of beta-2-pyridylalkylamines. Part I. Proceedings of the Staff Meetings of The Mayo Clinic 37:692 (Dec. 5) 1962.
3. Bertrand, R. A.: Meniere's disease: Subjective and objective evaluation of medical treatment with betahistine HCl. *Acta oto-laryng.* Supplement 305:48, 1972.

4. Wilmot, T. J.: An objective study of the effect of betahistine hydrochloride on hearing and vestibular function tests in patients with Meniere's disease. *J. Laryng. & Otol.* 85:369 (April) 1971.
5. Snow, J. B., Jr., and Suga, F.: Labyrinthine vasodilators. *A.M.A. Arch. Otolaryng.* 97:365 (May) 1973.
6. Martinez, D. M.: The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. *Acta oto-laryng.* Supplement 305:29, 1972.
7. Anderson, W. D., and Kubicek, W. G.: Effects of betahistine HCl, nicotinic acid, and histamine on basilar blood flow in anesthetized dogs. *Stroke* 2:409 (July-August) 1971.
8. Kubicek, W. G. and Anderson, W. D.: Blood Flow Changes into the Dog Labyrinthine Arteries. Presented at the American Academy of Ophthalmology and Otolaryngology, Chicago, October 29–November 2, 1967.
9. Guay, R. M.: Meniere's disease (Preliminary report of a new treatment). *Applied Therapeutics* 12:25 (August) 1970.
10. Hommes, O. R.: A study of the efficacy of betahistine in Meniere's syndrome. *Acta oto-laryng.* Supplement 305:70, 1972.

PRESCRIBING INFORMATION

DESCRIPTION AND CHEMISTRY: SERC is the proprietary name for a histamine-like drug generically designated as betahistine hydrochloride.

INDICATIONS: SERC may be of value in reducing the episodes of vertigo in Meniere's disease. No claim is made for the effectiveness of SERC in the symptomatic treatment of any form of vertigo other than that associated with Meniere's disease.

DOSAGE AND ADMINISTRATION: The usual adult dosage has been one to two tablets (4 mg. each) administered orally three times a day.

Recommended starting dose is two tablets three times daily. Therapy is then adjusted as needed to maintain patient response. The dosage has ranged from two tablets per day to eight tablets per day. No more than eight tablets are recommended to be taken in any one day.

SERC (betahistine hydrochloride) is not recommended for use in children. As with all drugs, SERC should be kept out of reach of children.

CONTRAINDICATIONS: Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using SERC. Although no causal relation has been established SERC is contraindicated in the presence of peptic ulcer and in patients with a history of this condition. SERC is also contraindicated in patients with pheochromocytoma.

PRECAUTIONS: Although clinical intolerance to SERC by patients with bronchial asthma has not been demonstrated, caution should be exercised if the drug is used in these patients.


USE IN PREGNANCY: The safety of SERC in pregnancy has not been established. Therefore, its use in pregnancy or lactation, or in women of childbearing age requires that its potential benefits be weighed against the possible risks.

ADVERSE REACTIONS: Occasional patients have experienced gastric upset, nausea and headache.

HOW SUPPLIED: Scored tablets of 4 mg. each in bottles of 100 tablets.

UNIMED Pharmaceuticals Limited
Dorval, Québec, H9P 2P4

7474A



Help prevent the storm of grand mal and psychomotor epilepsy with Mysoline

MYSOLINE (primidone USP) is a safe and effective anticonvulsant for the control of grand mal and psychomotor epilepsy in adults and children. For nearly 20 years MYSOLINE has been distinguished by its worldwide clinical record of effectiveness and safety. MYSOLINE is often effective where phenytoin or phenobarbital have failed. It is also frequently better tolerated, with minimal sedation. MYSOLINE increases the ability to carry out normal daily routines and improves outlook. In grand mal and psychomotor epilepsy, in focal epilepsy, including Jacksonian seizures, MYSOLINE gives excellent results. MYSOLINE allows the dosage flexibility needed to individualize therapy and it may be used alone or in combination with other anticonvulsants.

**a drug of choice for control and
maintenance in epilepsy.**

Mysoline*

Dosage: Adults and children over 8 years—week I: 250 mg h.s.; week II: 250 mg b.i.d.; week III: 250 mg t.i.d.; week IV: 250 mg q.i.d. Dosage may be increased until seizures are controlled but should not exceed 2 gm daily. Children under 8 years—half the adult dosage. In patients already receiving other anticonvulsants, dosage is gradually increased while the dosage of the other drug(s) is gradually decreased. **Adverse Effects:** Drowsiness, ataxia, vertigo, anorexia, irritability, general malaise, nausea and vomiting. These reactions are usually minor and transitory tending to disappear as therapy is continued or dosage is adjusted. No serious irreversible toxic reactions have been observed. (Occasionally, megaloblastic anemia has been reported, which is reversible by folic acid, 15 mg daily, while MYSOLINE is continued). As with any drug used over prolonged periods, routine laboratory studies at regular intervals are recommended. **Supplied:** Tablets—250 mg and 125 mg Suspension—250 mg/5ml. Complete prescribing information available on request.



* T M Reg

AYERST LABORATORIES,

division of Ayerst, McKenna & Harrison Limited, Montreal, Canada
Made in Canada by arrangement with IMPERIAL CHEMICAL INDUSTRIES LTD.



Quality has
no substitute



FROM TECA: A UNIQUE NEW DIRECT RECORDING ELECTROMYOGRAPH

Multiple, single sweep and continuous records appear rapidly on inexpensive 100 mm wide recording paper—without chemical processing—on the TECA Model TE-4 Direct Recording EMG—using a new inertialess recording method.

The new **TECA TE-4** permits, through modular plug-in design, one to four EMG channels. ■ Four traces of information are displayed on a large 7" cathode ray tube and may be automatically recorded simultaneously on 100 mm wide recording paper. ■ An electronic time ruler, a direct reading latency indicator, a delayed stimulus nerve stimulator with dual pulse capability, and a stabilized current muscle stimulator, permit a wide range of accurate rapid tests. ■ A two channel magnetic tape recorder is integrated into the System. ■ The TE-4 is of solid state design, making extensive use of integrated circuits. Modular plug-in construction simplifies service and permits easy expansion of capabilities by addition of modules listed. ■ Many of the above standard EMG features pioneered by TECA are further detailed in the TE-4 Specifications. Also included are new amplifier, stimulator, and System features and extended performance ranges offered. ■ Optional plug-ins: Evoked Potential Averager, Dual Pulse Train Stimulator, Signal Delay Unit (Delay Line), Integrator, Strain Gauge Amplifier.

PHOTOCOPY OF ACTUAL TRACING

TECA is an independent company concerned for the past 15 years with the development, production and maintenance of neuromuscular instrumentation and electrodes for clinical and research studies. TECA also offers a complete range of autoclavable electrodes.

GENIE AUDIO inc.

ELECTRO MEDICAL & ACOUSTIC INSTRUMENTS
9670 PELOQUIN, MONTREAL, CANADA H2C 2J4
PHONE: (514) 388-9212 CABLE: GENIODIO

TECA
CORPORATION

220 FERRIS AVE., WHITE PLAINS, N.Y.

Editorial Advisory Board

C. Miller Fisher
Boston

J. C. Richardson
Toronto

Frank B. Walsh
Baltimore

Donald B. Tower
Bethesda

Editorial Board

Murray L. Barr
London

Donald W. Baxter
Montreal

Claude Bertrand
Montreal

Guy Courtois
Montreal

John G. Humphrey
Toronto

Alan J. McComas
Hamilton

Douglas A. McGreal
Toronto

George Monckton
Edmonton

D. G. Montemurro
London

T. P. Morley
Toronto

Dwight Parkinson
Winnipeg

J. W. Phillis
Saskatoon

Louis J. Poirier
Quebec

T. B. Rasmussen
Montreal

Neil B. Rewcastle
Toronto

J. C. Szerb
Halifax

Margaret W. Thompson
Toronto

Juhn A. Wada
Vancouver

Leonhard S. Wolfe
Montreal

Associate Editor

André Barbeau
Montreal

Editor

R. T. Ross
Winnipeg

Editorial Assistant

Angela B. Ross
Winnipeg

THE EDITORIAL BOARD wishes to publish original work in the basic and clinical neurosciences on the understanding that it has not been and will not be published elsewhere. Review articles on timely subjects will be accepted. Manuscripts must be in duplicate including illustrations. One of the copies must be the original, ribbon copy. Manuscripts should be typed double spaced, on white paper.

Papers will be accepted in French or English. All papers should be accompanied by a short résumé in both languages. The résumé translation will be done by the editorial board if requested.

Papers should be identified only by the full name of the author, or authors, and the name of the place in which the work was done.

ILLUSTRATIONS: Photographs should be unmounted on glossy paper and show magnification scale. They should be marked on the back with figure number, title of paper and name of author.

Diagrams should be in India ink and large enough to be informative after reduction.

All illustrations should be referred to as figures, numbered consecutively, not included in the body of the text and all captions should be typed on a separate piece of paper.

Colored illustrations cannot usually be accepted unless the author is prepared to assist with the cost of reproduction.

REFERENCES to authors outside the context of the sentence should read (Name, Year). *i.e.* "However, a recent study (Bird and Iverson, 1975) showed a decreased, etc." Authors mentioned within the context of the sentence should read Name (Year). "*i.e.* . . . twenty years since Ecker and Reimshender (1951) demonstrated, etc." References should be typed in alphabetical order on a separate sheet and include author's name, initials, year, title in full, publication in full, volume, first and last page, *i.e.* Isacson, P. (1967). Myxoviruses and autoimmunity. *Progress in Allergy*, 10, 256-292.

Textbook references should include name of text, author's name, page number, publisher and city.

REPRINTS: Fifty reprints will be supplied free if ordered when the galley

proofs are returned. More may be ordered at a nominal charge. Corrections and changes in the galley proofs, apart from printer's errors may be charged to the author.

This journal is indexed by **Index Medicus, Excerpta Medica** and **Current Contents — Clinical Practice**.

SUBSCRIPTIONS: This journal is issued four times a year. The annual rate is \$24.00 (Canadian); Internes, Residents, Pre- and Post-Doctoral Students, \$12.00 per annum. Single copies \$10.00 each.

ADVERTISING: Enquiries regarding advertising space and rates should be directed to LEX LTD. VANCO PUBLICATIONS, 2 Tremont Crescent, Don Mills, Ontario M3B 2S1.

All communications, manuscripts, subscriptions, etc., should be sent to the Editor, at 1516 - 233 Kennedy St., Winnipeg, Canada R3C 3J5.

COPYRIGHT © 1976 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences.

The Possible Local Synthesis of Antibodies to Herpes Simplex Virus in Normal Cerebrospinal Fluid — Anthony Science Russell	219
A Theory of the Mechanism of Cerebral Vasospasm and Its Reversal, the role of Calcium and Cyclic AMP — Eric W. Peterson, Richard Leblanc	223
Neurofibrillary Tangles in the Dementia of "Normal Pressure" Hydrocephalus Melvyn J. Ball	227
Some Neurophysiological Effects of Cerebellar Stimulation in Man Adrian R. M. Upton, Irving S. Cooper	237
The Reactivity of Canine Cerebral Arteries to O₂ and CO₂ in Vitro P. Steinbok, M. J. Kendal, R. J. Clarke, S. J. Peerless	255
Supplemental Abstracts — Addendum to the Programme of the XI Congress of Neurological Sciences	
I.C.P. Aneurysms and Subarachnoid Hemorrhage — S. J. Peerless, N. F. Kassel	
Visual Evoked Potentials in Leber's Hereditary Optic Neuropathy — L. F. Dorfman	263
Announcements and Books Received	265
Quebec Cooperative Study on Friedreich's Ataxia — Phase One	269
Quebec Cooperative Study of Friedreich's Ataxia: Design of the Investigation — A. Barbeau	271
Nicolaus Friedreich and Degenerative Atrophy of the Posterior Columns of the Spinal Cord — F. Andermann	275
Clinical Description and Roentgenologic Evaluation of Patients with Friedreich's Ataxia — G. Geoffroy, A. Barbeau, G. Breton, B. Lemieux, M. Aube, C. Leger, and J. B. Bouchard	279
Genetic and Family Studies in Friedreich's Ataxia E. Andermann, G. M. Remillard, C. Goyer, L. Blitzler and A. Barbeau	287
Friedreich's Ataxia: Preliminary Results of Some Genealogical Research A. Barbeau, M. LeSeige, G. Breton, R. Coallier and J. P. Bouchard	303
Friedreich's Ataxia: Observations with Q and G Banding of Human Chromosomes M. Cadotte, A. Barbeau and G. Breton	307
Electroencephalographic Findings in Friedreich's Ataxia G. Remillard, F. Andermann, L. Blitzler and E. Andermann	309
Nerve Conduction Studies and Electromyography in Friedreich's Ataxia J. M. Peyronnard, J. P. Bouchard, L. Lapointe, A. Lamontagne, B. Lemieux and A. Barbeau	313
Cardiological Signs and Symptoms in Friedreich's Ataxia M. Cote, A. Davignon, K. Pecko-Drouin, A. Solignac, G. Geoffroy, B. Lemieux and A. Barbeau	319
Electrocardiographic and Vectocardiographic Findings in Friedreich's Ataxia S. Malo, Y. Latour, M. Cote, G. Geoffroy, B. Lemieux and A. Barbeau	323
Echocardiographic Findings in Friedreich's Ataxia H. F. Gattiker, A. Davignon, A. Bozio, J. Battle-Diaz, G. Geoffroy, B. Lemieux and A. Barbeau	329
Hemodynamic Findings in Friedreich's Ataxia M. Cote, A. Davignon, G. Elias, A. Solignac, G. Geoffroy, B. Lemieux and A. Barbeau	333
Cardiac Angiographic Findings in Friedreich's Ataxia R. Guerin, G. Elias, A. Davignon, M. Cote, G. Geoffroy, B. Lemieux and A. Barbeau	337
Pulmonary Function Studies in Friedreich's Ataxia M. A. Bureau, P. Ngassam, B. Lemieux and A. Trias	343
Pathology of the Heart in Friedreich's Ataxia: Review of the Literature and Report of One Case — G. Sanchez-Casis, M. Cote and A. Barbeau	349
Clinical Laboratory Findings in Friedreich's Ataxia — R. F. Butterworth, D. Shapcott, S. Melançon, G. Breton, G. Geoffroy, B. Lemieux and A. Barbeau	355
Glucose and Insulin Metabolism in Friedreich's Ataxia — D. Shapcott, S. Melançon, R. F. Butterworth, K. Khoury, R. Collu, G. Breton, G. Geoffroy, B. Lemieux and A. Barbeau	361
Bilirubin Metabolism in Friedreich's Ataxia — Preliminary Investigation A. Barbeau, G. Breton, B. Lemieux and R. F. Butterworth	365
Amino Acid Metabolism in Friedreich's Ataxia — B. Lemieux, A. Barbeau, V. Beroniade, D. Shapcott, G. Breton, G. Geoffroy and S. Melançon	373
Pyruvate Metabolism in Friedreich's Ataxia — A. Barbeau, R. F. Butterworth, T. Ngo, G. Breton, S. Melançon, D. Shapcott, G. Geoffroy and B. Lemieux	379
Friedreich's Ataxia 1976 — An Overview A. Barbeau	389
Index to Vol. 3	(i)